What Acella pharmaceuticals does

Acella Pharmaceuticals, LLC is a privately held U.S. specialty pharmaceutical company founded in 2007 and headquartered in Alpharetta, Georgia, operating as a wholly-owned subsidiary of Alora Pharmaceuticals. The company develops, manufactures, and distributes a diversified portfolio of generic and niche specialty products across six therapeutic categories: endocrinology (flagship NP Thyroid, a naturally-derived desiccated thyroid extract containing T4 and T3), dermatology, women's health, pain and gastrointestinal support, cough/cold, and nutritional supplementation. Distribution is conducted through U.S. wholesale pharmacy channels and retail pharmacies, with no international footprint disclosed.

The underlying technology is conventional small-molecule and biological-extract pharmaceutical manufacturing. NP Thyroid is the marquee product line — a porcine-derived desiccated thyroid extract offered in five dosage strengths (15 mg to 120 mg) — complemented by oral solutions, orally disintegrating tablets, sublingual tablets, topical washes, gels, creams, and combination cough/cold syrups. Pricing is not publicly disclosed; products are prescription pharmaceuticals moving through standard wholesale and pharmacy channels. Revenue, headcount growth metrics, and capital structure are not disclosed, but the company carries 51-100 employees and a leadership team with over a century of combined pharmaceutical industry experience, including executives drawn from Genentech, Aventis, Sanofi, Purdue Pharma, and Quintiles.

The business model is a classic specialty-generic commercialization operation: develop or in-license niche formulations, manufacture via contract partners (overseen by SVP Operations), and sell through an established wholesale-and-retail network managed by an EVP of Trade & Account Management. The company has pursued portfolio diversification as its primary growth lever rather than vertical integration, supported by an explicit business-development function that handles acquisitions, licensing, and joint ventures. Ownership resides entirely with Alora Pharmaceuticals, with no venture, private equity, or public-market capital structure identified in the available record.

Name

Acella pharmaceuticals

Legal name

Acella Pharmaceuticals, LLC

Website

https://acellapharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

Acella Pharmaceuticals is a U.S. specialty pharmaceutical company that develops, manufactures, and distributes generic and niche prescription products across endocrinology (NP Thyroid), dermatology, women's health, pain/GI, cough/cold, and nutritional categories through wholesale pharmacy channels, serving patients nationwide as a subsidiary of Alora Pharmaceuticals.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

akta.pro secondary industries

Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC), Gastrointestinal & Digestive Health (HLAIADAD)

Keywords

• Specialty pharmaceuticals
• Generic medications
• Thyroid hormone therapy
• Dermatology pharmaceuticals
• Women's health medications

Headquarters

HQ city

Alpharetta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Others

Distribution channels1 record

Marketing channels2 records

Core offering

Acella Pharmaceuticals develops, manufactures, and distributes a portfolio of specialty and generic pharmaceutical products across multiple therapeutic areas including endocrinology (NP Thyroid, a naturally-derived desiccated thyroid extract), dermatology (acne, antifungal, and skin-lightening treatments), women's health, pain relief (gabapentin), gastrointestinal (hyoscyamine), cough and cold remedies, and nutritional supplementation. The company operates as a subsidiary of Alora Pharmaceuticals and sells primarily through wholesale pharmacy distribution channels across the United States.

Product overview

Acella Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and distributes generic and specialty niche pharmaceutical products across multiple therapeutic categories. The company operates as a subsidiary of Alora Pharmaceuticals and focuses on delivering quality products at affordable prices. The portfolio includes thyroid health products (NP Thyroid® with multiple dosage strengths from 15mg to 120mg), pain management medications (Gabapentin, Hyoscyamine products), dermatological treatments (Ciclopirox, Hydroquinone, Salicylic Acid, and various Sodium Sulfacetamide-Sulfur combinations), cough and cold remedies (Brompheniramine combinations), and women's health products. NP Thyroid® is the flagship product, being a naturally-derived desiccated thyroid extract (DTE) containing both T4 and T3 hormones.

Differentiator

Problem solved

Functional benefit

Brands

• NP Thyroid: Thyroid Tablets, USP - A naturally-derived therapy containing T4 and T3 for thyroid health.

Products and services

• NP Thyroid® (Thyroid Tablets, USP) Naturally-derived desiccated thyroid extract (DTE) therapy containing both T4 (thyroxine) and T3 (triiodothyronine) hormones derived from porcine sources. Indicated for thyroid hormone replacement therapy in patients with hypothyroidism. Available in multiple dosage strengths: 15 mg (0.25 grain), 30 mg (0.5 grain), 60 mg (1 grain), 90 mg (1.5 grain), and 120 mg (2 grain).
• Gabapentin Oral Solution Oral solution formulation of gabapentin indicated for the treatment of seizures and neuropathic pain conditions. Marketed under the pain relief category for healthcare providers and patient use.
• Hyoscyamine Oral Tablets Oral tablet formulation of hyoscyamine sulfate indicated for treating gastrointestinal disorders including spasms and cramps.
• Hyoscyamine Sulfate ODT (Orally Disintegrating Tablet) Orally disintegrating tablet formulation of hyoscyamine sulfate designed for rapid absorption and treatment of gastrointestinal symptoms.
• Hyoscyamine Sulfate SL (Sublingual Tablet) Sublingual tablet formulation of hyoscyamine sulfate indicated for treatment of gastrointestinal and urinary tract disorders.
• Brompheniramine/Pseudoephedrine/Dextromethorphan Syrup Combination cough, cold, and allergy medication containing brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide. Available in 4 oz and 16 oz syrup formulations and 5 mL unit dose cups.
• BP 10-1 and BP Cleansing Wash Dermatological wash formulations containing benzoyl peroxide for treatment of acne and related skin conditions.
• Ciclopirox and Ciclopirox Treatment Kit Antifungal medication and complete treatment kit for fungal skin infections including athlete's foot, ringworm, and nail fungus.
• Hydroquinone 4% Cream Topical skin lightening cream for treatment of hyperpigmentation, brown spots, and melasma.
• Salicylic Acid 6% Gel Topical keratolytic gel for treatment of warts, acne, and thickened or callused skin.
• Sodium Sulfacetamide-Sulfur Product Line Diverse line of sodium sulfacetamide and sulfur combination topical products (cleansers, washes, creams, gels, and emollient creams) in various concentrations for treatment of acne, rosacea, and seborrheic dermatitis.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Alora PharmaceuticalscoreOthersAcella Pharmaceuticals is an Alora Pharmaceuticals company. The parent company provides strategic oversight and is developing an investigational DTE (desiccated thyroid extract) product called North Star for hypothyroidism with plans for FDA approval.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Viatris: One of the largest generic and specialty pharmaceutical companies in the world following the Mylan-Upjohn combination. Directly comparable to Acella as a multi-therapeutic generic and specialty player with a strong US wholesale distribution footprint and a portfolio strategy spanning both commoditized generics and niche specialty brands.
• Teva Pharmaceutical Industries: Largest generic drug manufacturer globally, with a significant specialty pharma franchise alongside generics. Directly comparable to Acella across multiple overlapping therapeutic categories (pain, dermatology, respiratory) and in the operating model of distributing through US wholesale pharmacy channels.
• Endo International: Specialty pharmaceutical company with a meaningful endocrinology and hormone replacement franchise. Highly relevant peer given Acella's NP Thyroid endocrinology focus and Endo's experience in specialty hormone products distributed through US pharmacy channels.
• Amneal Pharmaceuticals: Generic and specialty pharmaceutical manufacturer with deep presence in dermatology, neurology (gabapentin), endocrinology, and respiratory categories. Closely comparable to Acella's therapeutic mix and US wholesale distribution model.
• ANI Pharmaceuticals: US-focused specialty generic pharmaceutical company that develops, manufactures, and markets niche prescription and specialty products. Directly comparable to Acella in scale, therapeutic breadth, and go-to-market through US wholesale pharmacy channels.
• Lannett Company: Small-cap US generic pharmaceutical manufacturer with a portfolio spanning multiple therapeutic categories distributed through wholesalers and retailers. Directly comparable to Acella in size, product breadth, and reliance on a small leadership team to manage a multi-therapeutic book of business.
• Mallinckrodt: Specialty pharmaceutical company with a portfolio spanning branded specialty, generics, and niche therapeutic categories including endocrinology. Comparable to Acella in its mix of commoditized generics and niche specialty products distributed through US pharmacy channels.
• IBSA Pharma: Specialty pharmaceutical company that markets Armour Thyroid and other desiccated thyroid extract (DTE) products in the US. The closest direct head-to-head competitor to Acella's NP Thyroid in the niche DTE category for hypothyroidism treatment.

Emerging players

• Padagis: Recently independent specialty/generic pharmaceutical company (former Perrigo generics) with a focused portfolio in dermatology and adjacent categories. Comparable to Acella in scale, go-to-market, and the opportunity set for an independent specialty platform post-spin.

Broad incumbents

• AbbVie: Global biopharmaceutical incumbent that markets Synthroid (levothyroxine), the dominant FDA-approved thyroid hormone replacement therapy. While broader in portfolio and capabilities, AbbVie is the most direct incumbent in Acella's core endocrinology/wholesale thyroid channel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/acella-pharmaceuticals-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acella pharmaceuticals